64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing
Summary
SAN FRANCISCO, January 19, 2022--(BUSINESS WIRE)--64x Bio, a synthetic biology company, today announced the close of a $55 million Series A financing round to fund the expansion of its VectorSelect™ platform, a novel cell line engineering technology which has the potential to revolutionize the economics and accessibility of gene therapy. 64x will also use the proceeds to dramatically grow its employee base and partnership efforts with leading gene therapy companies, through the expansion of additional intellectual property, operations, and business development infrastructure. "With the support of our incredible investors and scientific team, we aim to become the leading developer of vector manufacturing cell lines, to revolutionize the economics of gene therapy and the reach of these lifesaving medicines to patients." This limitation is a major bottleneck for the gene therapy field, which relies heavily on vectors," said Sander Duncan, General Partner at Lifeforce Capital, who joins 64x’s Board of Directors. 64x then applies computational tools to its growing CellMap™ database of proprietary mutant data to filter trillions of possible solutions into millions of screenable genetic combinations, further increasing the speed and efficacy of cell line development.